Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Drugs for Cardiology/Vascular Diseases in Phase II Clinical Development in AUSTRALIA

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Cynata Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Interphex

Participation Not Confirmed

Update your events

Cynata Therapeutics welcomes UK Regulatory Authority approval of Phase 2 clinical trial in critical limb ischaemia

Contact the Supplier

Lead Product(s): CYP-002

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 14, 2020

Details:

Cynata Therapeutics (CYP) has received approval from the U.K. Medicines and Healthcare products Regulatory Agency to begin the phase 2 trial of CYP-002.